{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010097","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.164945+00:00","generated_at":"2026-06-04T17:30:50.584220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Azitra reports FY2023 net loss $11.3M, cash $1.8M; advances ATR-12 Phase 1b and ATR-04 IND","bullets":["Net loss $11.3M vs $10.7M in 2022; service revenue from related party $0.7M.","Cash and equivalents $1.8M at Dec 31, 2023, plus $4.4M net from Feb 2024 follow-on.","ATR-12 for Netherton syndrome: Phase 1b trial enrolling ~12 patients; safety data in late 2024.","ATR-04 for EGFRi-associated rash: IND submission mid-2024; first-in-human trial by late 2024/early 2025.","Bayer joint development agreement progressing; expect license agreement with upfront payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010097","json":"https://secwatch.observer/filing/0001493152-24-010097.json","markdown":"https://secwatch.observer/filing/0001493152-24-010097.md","text":"https://secwatch.observer/filing/0001493152-24-010097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/0001493152-24-010097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T17:30:50.584220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7732bda0785a7c446b23ab52940e8561325d5f2","claim":"Azitra, Inc. reported the full year ended December 31, 2023 results: revenue $0.7 million, net income $11.3 million.","evidence_excerpt":"■ Execution of a licensing agreement with upfront payment Financial Results for the Year Ended December 31, 2023 ● Service Revenue – Related Party : The Company generated $0.7 million of service revenue during the year ended December 31, 2023, compared to $0.3 million for the comparable period in 2022. ● Research and Development (R&D) expenses : R&D","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/0001493152-24-010097-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"$11.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}